Shingles and Pneumonia Vaccines Linked to Lower Dementia Risk, New Research Suggests
November 9, 2025 - Emerging research is suggesting a surprising connection between common vaccinations – those for shingles and pneumonia – and a reduced risk of dementia. A new study, published recently, adds to a growing body of evidence that these vaccines may offer a protective effect against the debilitating neurological condition.
The study, analyzing the health records of over 400,000 adults in the United States, found that individuals who received either the shingles or pneumonia vaccine had a significantly lower risk of being diagnosed with dementia in the years following vaccination.Specifically, the shingles vaccine was associated with a 26% reduction in dementia risk, while the pneumonia vaccine showed a 13% reduction.
“This is compelling enough that physicians may begin discussing dementia prevention as an added benefit with their patients,” said Dr.Michael Jena, the Joseph P.Newhouse Professor of Health Policy at Harvard Medical School. He noted he recently introduced the research to a group of residents unfamiliar with the link.
the findings build upon previous research, including a 2017 study co-authored by Dr. Geldsetzer examining over 280,000 adults in Wales.That study revealed a 20 percent lower risk of dementia over a seven-year period among those who received the shingles vaccine.
Researchers found the protective effects of the vaccines appeared to correlate with the duration of their immunity. As vaccine protection waned, so too did the observed benefits against dementia.
While the exact mechanism behind this connection remains unclear, scientists hypothesize that the vaccines may stimulate the immune system in a way that benefits brain health.
Despite the promising results,some experts caution against over-interpretation and potential politicization of the findings. Dr.AM Barrett, chair and professor of neurology at UMass Chan Medical School, expressed concern that the issue could fuel vaccine skepticism.
“Sadly,” she said, “people who are not personally affected by dementia may see this as an attempt to persuade them to receive an unnecessary vaccination.” Though, she emphasized the relatively low cost and widespread availability of the vaccines. “You want to be able to play with your grandchildren for five more years and be able to drive well for another five years,” she said. ”This is priceless.”
The research offers a potentially significant, and relatively accessible, avenue for dementia prevention, a field currently lacking highly effective interventions.
About the Author:
Akilah Johnson is a national reporter who investigates the impact of racism and social inequality on health for The Washington Post. She joined the Post in 2021 after working at ProPublica, where she won a George Polk Award and a National magazine Award and was nominated for the Pulitzer Prize for her inquiry into the impact of Covid-19 on Black Americans.
This article was first published in English on November 9, 2025 at the “Washingtonpost.com” and is now available in translation to readers of the IPPEN.MEDIA portals.
